Literature DB >> 7714616

Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Case report.

K Kovacs1, L Stefaneanu, E Horvath, M Buchfelder, R Fahlbusch, W Becker.   

Abstract

A 14-year-old girl presented with a rapidly growing, invasive prolactin-producing pituitary tumor that failed to respond to dopamine agonist medication. Histological, immunocytochemical, and ultrastructural studies of the surgically removed tissue revealed a pleomorphic, chromophobic, or slightly acidophilic pituitary tumor that was immunoreactive for prolactin and that, according to electron microscopy, consisted of atypical lactotrophs showing no evidence of cell shrinkage. In situ hybridization demonstrated large amounts of prolactin messenger ribonucleic acid (mRNA), moderate amounts of estrogen receptor mRNA and dopamine (D2) receptor mRNA, and an absence of growth hormone mRNA in the tumor cells. Because D2 receptor mRNA was present in the tumor, causes other than D2 receptor loss may have been responsible for the resistance of the lactotrophs to dopamine agonist administration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714616     DOI: 10.3171/jns.1995.82.5.0886

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Dopamine D2 receptor gene expression in human adenohypophysial adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; M Buchfelder; R Fahlbusch; L Lancranjan
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.

Authors:  D Kojo Hamilton; Mary Lee Vance; Paul T Boulos; Edward R Laws
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

4.  Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.

Authors:  Lin Cai; Zhi Gen Leng; Yu Hang Guo; Shao Jian Lin; Ze Rui Wu; Zhi Peng Su; Jiang Long Lu; Li Fei Wei; Qi Chuan Zhuge; Kunlin Jin; Zhe Bao Wu
Journal:  Endocrine       Date:  2015-12-12       Impact factor: 3.633

Review 5.  Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.

Authors:  L A Behan; M S Draman; C Moran; T King; R K Crowley; E P O'Sullivan; D Smith; C J Thompson; A Agha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

6.  Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.

Authors:  Jun Gao; Yang Liu; Gaijing Han; Kan Deng; Xiaohai Liu; Xinjie Bao; Ming Feng; Yong Yao; Wei Lian; Bing Xing; Xiang Lv; Renzhi Wang
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.